Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × Immune Checkpoint Inhibitors × Clear all

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Phase 2 Not yet recruiting

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04715633 2024-07-09

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05371197 2022-05-12

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms